Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a new class of drugs that might have a potential beneficial effect on bone metabolism. Data on the effect of GLP-1 RAs and fracture risk are lacking. The aim of the present study was to investigate the association between the use of GLP-1 and the risk of fracture. A case-control study was performed using Danish National Health Service data. Cases were those who sustained a fracture and controls were those without a fracture during the study period (2007-2011), all aged 18 years and above. Conditional logistic regression estimated the odds ratios (OR) of fracture with current use of DPP4-I use. Analyses were adjusted for comorbidities and recent drug use. Among cases (n = 229,114), there were 6993 current non-insulin anti-diabetic drug (NIAD) users (excluding incretin users) and 255 GLP-1 RA users. Similarly, among controls (n = 229,114), 7209 were NIAD users (excluding incretin users) and 220 were GLP-1 RA users. Current GLP-1 RA use was not associated with a decreased risk of fracture [adjusted (adj.) OR 1.16; 95% CI 0.83-1.63]. Osteoporotic fracture risk was also not associated with current GLP-1 RA use (adj. OR 0.78; 95% CI 0.44-1.39). In our nation-wide case-control study, we identified that the use of GLP-1 RA was not associated with fracture risk as compared to the use of other anti-hyperglycemic drugs. Additionally, current GLP-1 RA use, stratified by cumulative or average daily dose, is not associated with fracture risk. Further research should focus on long-term use of GLP-1 RA and fracture risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 1×
“Our results are also in keeping with a large clinical trial (n = 16,492) on the effect of a DPP4-I, saxagliptin, which showed no difference in risk of fracture with the use of DPP4-I use and placebo [24].”
ResultSmoking and fracture risk: a meta-analysis
Kanis, J. A., Johnell, O., Oden, A., Johansson, H., De Laet, C., Eisman, J. A., Fujiwara, S., Kroger, H., McCloskey, E. V., Mellstrom, D., et al. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1640-3 · Cited by 999 · cited 1×
“Smoking is a risk factor of fracture [33], but there is no evidence that GLP-1 RA users have different smoking behaviors than the patients treated with other anti-hyperglycemic drugs.”
BackgroundMabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
Effects of exercise on fracture reduction in older adults: A systematic review and meta-analysis
Kemmler, W., Häberle, L., & von Stengel, S. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2248-7 · Cited by 174
Kim, J.-Y., Lee, S.-K., Jo, K.-J., Song, D.-Y., Lim, D.-M., Park, K.-Y., Bonewald, L. F., & Kim, B.-J. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.001 · Cited by 137
Driessen, J. H. M., Henry, R. M. A., van Onzenoort, H. A. W., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G. M., & de Vries, F. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9993-5 · Cited by 79 · cited 2×
“Additionally, the present results are also supported by the results of a cohort study which was not able to show a decreased risk of fracture with the use of GLP-RA as compared to the use of other anti-hyperglycemic drugs [12] and a cohort study that compared the use of DPP4-I to the use of other antihyperglycemic dru…”
BackgroundResultSelf-citation
Cited by
Bone fragility in diabetes: novel concepts and clinical implications
Hofbauer, L. C., Busse, B., Eastell, R., Ferrari, S., Frost, M., Müller, R., Burden, A. M., Rivadeneira, F., Napoli, N., & Rauner, M. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00347-8 · Cited by 440
Self-citationEbeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 338
Hansen, M. S., Wölfel, E. M., Jeromdesella, S., Møller, J.-J. K., Ejersted, C., Jørgensen, N. R., Eastell, R., Hansen, S. G., & Frost, M. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102624 · Cited by 115
The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review
Daniilopoulou, I., Vlachou, E., Lambrou, G. I., Ntikoudi, A., Dokoutsidou, E., Fasoi, G., Govina, O., Kavga, A., & Tsartsalis, A. N. (2022) · Medicina · doi:10.3390/medicina58020224 · Cited by 74
“No association was found between GLP1RAs and fracture risks in both studies conducted by Driessen et al. (2015) [43,44] (Table 1).”
BackgroundWang, N., Gao, J., Jia, M., Ma, X., Lei, Z., Da, F., Yan, F., Zhang, H., Zhou, Y., Li, M., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485776 · Cited by 42
Metadata
- Authors
- Driessen, J. H. M., van Onzenoort, H. A. W., Starup-Linde, J., Henry, R., Burden, A. M., Neef, C., van den Bergh, J. P., Vestergaard, P., & de Vries, F.
- Venue
- Calcified Tissue International
- Published
- 2015-07-17
- Volume
- 97
- Issue
- 5
- Pages
- 506-515
- ISSN
- 0171-967X (ISSN-L)
- 1432-0827
- OpenAlex
- W1951484771
- Cited by
- 76
- References
- 7
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs. https://app.cochat.ai/papers/10.1007/s00223-015-0037-y
- The paper
- Driessen, J. H. M., van Onzenoort, H. A. W., Starup-Linde, J., Henry, R., Burden, A. M., Neef, C., van den Bergh, J. P., Vestergaard, P., & de Vries, F. (2015). Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs. Calcified Tissue International. https://doi.org/10.1007/s00223-015-0037-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.